Stocktoria
Intellia Therapeutics, Inc. NTLA
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 2016-05-06
Intellia Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $67.7M | $57.9M | $36.3M | $52.1M | $33.1M |
| R&D expense | $388.9M | $466.3M | $435.1M | $420.0M | $229.8M |
| Operating income | -$441.0M | -$534.3M | -$515.3M | -$458.2M | -$267.9M |
| Income tax | $0 | — | — | — | — |
| Net income | -$412.7M | -$519.0M | -$481.2M | -$474.2M | -$267.9M |
| EPS (diluted) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
| Operating cash flow | -$394.7M | -$348.9M | -$394.1M | -$333.3M | -$225.0M |
| Free cash flow | -$395.9M | -$354.7M | -$408.1M | -$346.8M | -$237.8M |
| Cash & equivalents | $155.5M | $189.2M | $226.7M | $523.5M | $123.4M |
| Total assets | $842.1M | $1.2B | $1.3B | $1.5B | $1.3B |
| Total liabilities | $170.7M | $319.1M | $250.8M | $284.5M | — |
| Shareholders' equity | $671.4M | $872.0M | $1.1B | $1.2B | $1.0B |
Source: SEC EDGAR filings · CIK 0001652130 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.